Trials / Withdrawn
WithdrawnNCT01110044
Study of a Birth Dose of GlaxoSmithKline Biologicals' 251154 Vaccine
Immunogenicity and Safety of a Birth Dose of GlaxoSmithKline Biologicals' Reduced-antigen-content Tri-component Pertussis (251154) Vaccine
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 2 Days – 5 Days
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to evaluate the safety and immunogenicity of a birth dose of GSK Biologicals' reduced-antigen-content tri-component pertussis (251154) vaccine followed by routine paediatric vaccination.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | 251154 vaccine | Intramuscular, single dose |
| BIOLOGICAL | Infanrix hexa™ | Intramuscular, four doses |
| BIOLOGICAL | Synflorix™ | Intramuscular, four doses |
| BIOLOGICAL | Rotarix™ | Oral, two doses |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2012-08-01
- Completion
- 2012-08-01
- First posted
- 2010-04-23
- Last updated
- 2015-03-27
Source: ClinicalTrials.gov record NCT01110044. Inclusion in this directory is not an endorsement.